Combination of mesenchymal stem cells and nicorandil: an emerging therapeutic challenge against COVID-19 infection-induced multiple organ dysfunction.
Stem Cell Res Ther
; 12(1): 404, 2021 07 15.
Article
in English
| MEDLINE | ID: covidwho-1314278
ABSTRACT
The recent COronaVIrus Disease (COVID)-19 pandemic has placed an unprecedented burden on the drug development opportunity to prevent the onset of multi-organ failure.Emerging experimental reports have highlighted the beneficial effects of mesenchymal stem cell (MSC) administration against COVID-19. MSCs and their derived exosomes may attenuate SARS-CoV-2-induced inflammatory response through managing the immune cell function and cytokine expression. Although these are promising results, the exposure of MSCs to chemical compounds with pharmacological activities may further improve their homing, survival, and paracrine machinery.Nicorandil (N-[2-hydroxyethyl]-nicotinamide nitrate), an established adenosine triphosphate-sensitive potassium channel opener, is recently hypothesized to modulate inflammation as well as cell injury and death in COVID-19-affected lungs through inhibiting reactive oxygen species levels and apoptosis. Since it also exerts protective effects against hypoxia-induced MSC apoptosis, we assumed that transplanted MSCs combined to long-term nicorandil administration may survive longer in a severely inflamed microenvironment and have more beneficial effects in the treatment of SARS-CoV-2 infection than MSCs alone.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mesenchymal Stem Cell Transplantation
/
Mesenchymal Stem Cells
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Stem Cell Res Ther
Year:
2021
Document Type:
Article
Affiliation country:
S13287-021-02482-8
Similar
MEDLINE
...
LILACS
LIS